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Abstract
Introduction—Altered DNA methylation (DNAm) levels of hypothalamic-pituitary-adrenal 
(HPA) axis genes has been associated with exposure to childhood maltreatment (CM) and 
depression; however, it is unknown whether CM and depression have joint and potentially 
interacting effects on the glucocorticoid receptor (NR3C1) DNAm. We investigated the impact of 
CM and lifetime major depressive disorder (MDD) on NR3C1 DNAm and gene expression (GE) 
in 147 adult participants from the Detroit Neighborhood Health Study.
Methods—NR3C1 promoter region DNAm was assessed via pyrosequencing using whole blood-
derived DNA. Quantitative RT-PCR assays measured GE from leukocyte-derived RNA. Linear 
regression models were used to examine the relationship among CM, MDD, and DNAm.
Results—Both CM and MDD were significant predictors of NR3C1 DNAm: CM was associated 
with an increase in DNAm in an EGR1 transcription factor binding site (TFBS), whereas MDD 
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was associated with a decrease in DNAm downstream of the TFBS. No significant CM-MDD 
interactions were observed. CM alone was associated with significantly lower NR3C1 GE.
Limitations—Our report of CM is a retrospective self-report of abuse, which may introduce 
recall bias. DNAm was measured in whole blood and may not reflect brain-derived DNAm levels.
Conclusions—CM and MDD are both associated with altered DNAm levels in the NR3C1 
promoter region, however the location and direction of effects differ between the two exposures, 
and the functional effects, as measured by GE, appear to be limited to CM exposure alone. CM 
exposure may be biologically embedded in this key HPA axis gene.
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1. Introduction
There is a well-established link between early life adversity and poor mental health later in 
life (Afifi et al., 2008; McEwen, 2003). Specifically, childhood maltreatment has been 
strongly associated with the onset of major depressive disorder (MDD) (Kendler et al., 2004; 
Nemeroff, 2004) and other mental illnesses during adulthood, including posttraumatic stress 
disorder (PTSD) (Green et al., 2010), bipolar disorder (Afifi et al., 2008), and anxiety 
disorders (Kessler et al., 1997). Several decades of work in rodents, humans, and non-human 
primates has demonstrated the importance of early environment on the molecular pathways 
regulating the stress response (reviewed in (Klengel et al., 2014)). These studies have largely 
focused on examining the epigenetics of hypothalamic-pituitary-adrenal (HPA) axis genes 
due to the primary role of the HPA axis in regulating the body's stress response. 
Dysregulation of the HPA axis results in an altered stress response (Nemeroff, 2004), 
producing an increased risk for mood and anxiety disorders, as well as physical disorders 
such as diabetes and cardiovascular disease (Irwin and Cole, 2011; Nemeroff, 2004; Radtke 
et al., 2011). However, the molecular mechanisms that underlie HPA axis dysregulation, and 
their possible associations with commonly occurring mental disorders such as depression 
remain unclear. DNA methylation is a stable, but modifiable, epigenetic mark that is 
characterized by a chemical alteration to the nucleotides that comprise DNA (Whitelaw and 
Whitelaw, 2006). This chemical modification does not alter the underlying DNA sequence 
but rather serves to regulate chromatin structure and DNA accessibility, often resulting in 
altered transcription. DNA methylation is characterized by the addition of a methyl group, –
CH3, to the 5′ position of cytosine – typically when cytosine is coupled to guanine on the 
same strand of DNA – and is stable over time (Heijmans et al., 2008; Tyrka et al., 2008), 
tissue specific (Gama-Sosa et al., 1983), and responsive to environmental exposures (Fraga 
et al., 2005). From a functional perspective, DNA methylation of transcription factor binding 
sites (TFBS) within gene promoter regions typically results in reduced gene expression 
(Brenet et al., 2011), and, in particular, has been associated with early life changes to stress-
relevant phenotypes that persist into adulthood (Weaver et al., 2004). Thus, as a stable, but 
modifiable, molecular mechanism with functional effects, epigenetic regulation is a potential 
contributor to the etiology of mental disorders resulting from adverse early life experiences.
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A substantial body of evidence has shown that early life adversity, in particular childhood 
maltreatment, is associated with DNA methylation differences in HPA axis gene nuclear 
receptor subfamily 3, group member 1 (NR3C1), whose product is commonly known as the 
glucocorticoid receptor (McGowan et al., 2009; Tyrka et al., 2012). The glucocorticoid 
receptor plays an important role in the body's stress response as it not only binds to the stress 
hormone cortisol, but also modulates the negative feedback of the HPA axis. High levels of 
cortisol tamp down the stress response by reducing corticotropin releasing hormone (CRH), 
the hormone released by the hypothalamus that triggers the stress response cascade (Binder, 
2009); this negative feedback is facilitated by the binding of cortisol to the glucocorticoid 
receptor (Binder, 2009). Initial rodent studies in NR3C1 demonstrated that early 
environment, specifically level of maternal care, was associated with alterations to NR3C1 
DNA methylation, resulting in changes in stress sensitivity that last into adulthood (Weaver 
et al., 2004). Similarly, in humans, maternal depressed/anxious mood during the third 
trimester was associated with increased NR3C1 DNA methylation in a TFBS in cord 
derived-blood, and with increased infant cortisol responses 3 months postnatally (Oberlander 
et al., 2008). Subsequent human studies have confirmed exposure to childhood maltreatment 
and other early life adversities are associated with increased NR3C1 DNA methylation 
measured in both blood and post mortem brain tissue (Labonte et al., 2012; Martin-Blanco et 
al., 2014; McGowan et al., 2009; Tyrka et al., 2012). Maternal experiences during pregnancy 
have also been associated with DNA methylation differences in NR3C1 in their offspring, 
reviewed and summarized in a recent meta-analysis (Palma-Gudiel et al., 2015). These 
studies underscore the importance of early life environments and, in particular, the long-term 
impact of early life adversity (ELA)-induced changes to DNA methylation on mental health.
Despite the extensive research supporting the link between ELA and altered DNA 
methylation, few studies have examined the link between depression and NR3C1 DNA 
methylation. To date, only two studies have directly examined NR3C1 promoter region DNA 
methylation and MDD. A recent study examined NR3C1 DNA methylation and 
hippocampal volume in a group of participants with MDD compared to healthy controls, 
finding MDD patients had significantly lower levels of DNA methylation within the 
promoter region of NR3C1 (Na et al., 2014). Additionally, a second paper examined NR3C1 
DNA methylation in a group of participants with and without MDD, reporting a significant 
increase in NR3C1 DNA methylation at a single CpG site associated with the disorder 
(Nantharat et al., 2015). These studies report opposite associations between MDD and 
NR3C1 DNA methylation levels measured in blood; however, the relationship among 
childhood maltreatment, MDD, and NR3C1 DNA methylation was not addressed in either 
work. To address this gap in knowledge, we sought to examine the impact of childhood 
maltreatment and MDD on NR3C1 DNA methylation and gene expression levels among 
adults. We hypothesized that (1) childhood maltreatment and MDD affect NR3C1 DNA 
methylation in a joint and potentially interacting manner, and, secondarily, that (2) DNA 
methylation differences resulting from childhood maltreatment and/or MDD would 
contribute to functional consequences in NR3C1 as measured by gene expression levels.
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2. Methods
2.1. Participant selection
The Detroit Neighborhood Health Study (DNHS) was approved by the institutional review 
boards at the University of Michigan and the University of North Carolina at Chapel Hill. 
Participants (N=152) were selected from the DNHS, a longitudinal, population-based 
representative sample of adult residents from Detroit, MI (Uddin et al., 2010). All 
participants provided informed consent prior to participation in the DNHS. Selection for 
inclusion within this study was based on the availability of whole-blood derived DNA, 
leukocyte-derived RNA, and complete survey data regarding childhood maltreatment and 
depression histories. In our study population of 152 DNHS participants, 94 were female and 
58 were male; 26 self-identified as European-American, 116 as African-American, and 10 as 
“other”. The average age was 49.6 years.
2.2. Childhood maltreatment
Participant survey data regarding childhood maltreatment history were collected via 
structured telephone interviews on the severity, duration, and frequency of each event type. 
Assessment of childhood maltreatment was based on the Conflict Tactics Scale (CTS) 
(Straus, 1979) and the Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 1997), as 
previously described (Keyes et al., 2012; Uddin et al., 2013). CTS items assessed physical 
and emotional abuse before age 11, with responses rated on a 5-point scale. CTQ assessed 
physical and sexual abuse before age 18, rating responses on a 3-point scale. The childhood 
maltreatment score variable is a continuous measure ranging from 0 to 22, as previously 
described (Keyes et al., 2012; Uddin et al., 2013). In this study, participants with childhood 
maltreatment exposure (N=76) were defined as any individual belonging to the upper 
quartile for childhood maltreatment score within the full DNHS survey sample (N=1547). 
Participants without childhood maltreatment exposure (N=76) belonged to the bottom 
quartile of childhood maltreatment score within the full DNHS survey sample.
2.3. Depression measure
MDD was assessed using the Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001) 
with additional questions that assessed timing and duration of symptoms, consistent with 
DSM-IV criteria (American Psychiatric, 1994). The PHQ-9 is a 9-item instrument rating 
responses on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day), with total 
scores ranging from 0 to 27. The measure has been previously validated (Uddin et al., 2011). 
MDD was defined as the presence of lifetime MDD (cases N=76, controls N=76).
2.4. Antidepressant medication
Participant medication information was taken during the in-home visit at the time of biologic 
sample collection (see Section 2.5). Participants were instructed to provide all current 
prescribed and over the counter medication to the phlebotomist, who recorded the 
medication name, dosage, and frequency each medication was taken. Antidepressant 
medication use for this study was determined based on participant medication information 
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from the appropriate wave. SAS Enterprise Guide 7.1 (SAS Institute Incorporated, NC) was 
used to code medications as antidepressants.
2.5. Sample preparation
2.5.1. DNA—Whole blood was collected via venipuncture from study participants during 
scheduled in home visits by a trained phlebotomist. DNA was isolated from whole blood 
using Qiagen's QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) and LifeSciences's 
Quickgene DNA Whole Blood Kit (St. Petersburg, FL) following the manufacturer's 
recommended protocols. DNA concentrations were verified using the NanoDrop 1000 
(ThermoScientific, Waltham, MA) following the manufacturer's recommended protocol.
2.5.2. RNA—RNA was obtained from leukocytes using Leukolock kits following the 
manufacturer's alternative protocol to preserve total RNA (Ambion, Austin, TX). Quality 
control criteria was used to ensure high quality RNA was obtained, including a RNA 
integrity number (RIN) ≥ 5, 28s/18s ≥ 1.0, and 260/280 ≥ 1.7 (Fleige and Pfaffl., 2006; 
Fleige et al., 2006). RNA sample RIN values and 28s/18s ratios were calculated using the 
2100 Bioanalyzer (Agilent, Wilmington, DE) to determine RNA quality. RNA concentration 
for each sample was determined using the NanoDrop 1000 (ThermoScientific).
2.5.3. Peripheral blood mononuclear cell counts—At the time of blood draw, two 
FICOLL gradient containing 8 ml BD Vacutainers CPT™ with sodium citrate (Franklin 
Lakes, NJ) were used for the collection of peripheral blood mononuclear cells (PBMC) 
samples. Participant tubes were spun in a centrifuge within two hours of collection and 
processed immediately. During processing, mononuclear cells were isolated, assessed for 
viability, and counted using Invitrogen's Countess automated cell counter (Carlsbad, CA). A 
small number of PBMC samples used in this study were measured using TPP PCV Packed 
CellVolume tubes (Trasadingen, Switzerland) and assessed for viability using a 
hemacytometer (Fisher Scientific, Pittsburgh, PA).
2.5.4. Bisulfite conversion—750 ng of DNA from each participant was bisulfite 
converted using Qiagen's Epitect Bisulfite Kit following the manufacturer's recommended 
protocol. Negative controls containing RNA/DNA free water in place of DNA were included 
with each bisulfite conversion. High and low methylation control DNA purchased from 
Zymo Research (Irvine, CA) were bisulfite converted along with the participant samples in 
order to assess assay performance.
2.6. PCR amplification and pyrosequencing
DNA methylation for 13 CpG sites within the promoter region of NR3C1 were assessed via 
pyrosequencing (CHR5: 142,783,655–142,783,501). The 13 CpG sites targeted in our 
analyses encompass a 155 bp region and contain an EGR1 TFBS (also known as NGF1-A) 
(Fig. 1). This locus has been the focus of several other previous studies (McGowan et al., 
2009; Oberlander et al., 2008; Radtke et al., 2011; Tyrka et al., 2012). Primers were newly 
developed for this study (see below) using the PyroMark Q24 Assay Design Software 2.0 
(Qiagen). Validation experiments were carried out according to recommendations in the 
PyroMark manual on all custom assays to ensure high quality primers were used. PCRs were 
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run in duplicate and contained 20 ng of bisulfite converted DNA as starting template. No 
template controls were also run in duplicate with each set of PCRs as a negative control. 
Each primer was also tested using bisulfite converted DNA from high and low methylation 
controls (Zymo). Qiagen's PyroMark Q24 Pyrosequencer was used to detect DNA 
methylation levels following manufacturer's protocols and default settings.
1 to 4CpG.
Forward PCR primer: 5′-AGTTTTAGAGTGGGTTTGGAG-3′.
Reverse PCR primer (biotinylated): 5′-
ACCACCCAATTTCTCCAATTTCTTTTCTC-3′.
Sequencing primer: 5′-GAGTGGGTTTGGAGT-3′.
5 to 13CpG.
Forward PCR primer: 5′-GGGGGAGGGAAGGAGGTA-3′.
Reverse PCR primer (biotinylated): 5′-CCCCCAACTCCCCAAAAA-3′.
Sequencing primer: 5′-GGGAGGGAAGGAGGTAG-3′.
9 to 13CpG.
Forward PCR primer: 5′-GGAAGGAGGTAGAGAGAAAAGAAATTGG-3′.
Reverse PCR primer (biotinylated): 5′-CCCCCAACTCCCCAAAAA-3′.
Sequencing primer: 5′-GGAGAAATTAGGTTTTTTTAA-3′.
PCR Program: (same for all primer sets).
Initial 15 minutes 95°C
Denaturation 30 seconds 94°C
Annealing 30 seconds 56°C 50 cycles
Extension 30 seconds 72°C
Final 10 minutes 72°C
Hold 4°C indefinitely
2.7. Reverse transcription and Real Time PCR
To analyze gene expression levels, RNA was reverse transcribed into cDNA following the 
manufacturer's protocol using the High Capacity Reverse Transcription Kit purchased from 
Applied Bio-Systems (Foster City, CA). Ready-made Taqman gene expression assays 
(Applied Biosystems) were used to measure relative transcript levels of the target gene 
NR3C1 (Hs00353740_m1) and the control gene PGK1 (Hs00943178_g1) run in separate 
wells. The NR3C1 Taqman assay specifically targeted the GRα isoform. Reactions were 
performed in triplicate for each locus, with each replicate tested in a 20 µl reaction 
containing 10 ng of participant cDNA. Reactions were run on a HT7500 Fast Real Time 
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PCR machine (Applied BioSystems, Foster City, CA) following the manufacturer's 
recommended protocol for standard reactions.
2.8. Primary analyses
Previous studies have reported significant associations between DNA methylation at CpG 
sites 1–4 and early life experiences, while CpG sites 5–13 have been grouped together for 
exploratory analyses (McGowan et al., 2009; Oberlander et al., 2008; Tyrka et al., 2012). 
Additionally, the ERG1 TFBS, previously implicated in multiple studies of early-life 
adversity and NR3C1 DNA methylation (Romens et al., 2015; Tyrka et al., 2012; van der 
Knaap et al., 2014) encompasses CpG site 3 and 4, while other TFBS are located within bin 
5–13 as identified using the UCSC genome browser track “Encode Regulation” ChIP-seq 
data. The TFBSs within the 5–13CpG region have been confirmed in a variety of cell lines 
including those derived from blood and brain tissues. Similar binning approaches have been 
applied to analyses of stress-related effects on other HPA axis genes, in which functionally 
distinct regions are grouped together in bins (e.g. FKBP5; (Klengel et al., 2013; Yehuda et 
al., 2015). Therefore, in our study, DNA methylation levels were analyzed in two bins, 1–4 
and 5–13. Bin 1–4 was created by averaging DNA methylation levels within participants 
across all 4 sites. To create bin 5–13, we pooled data generated from both the 5to13CpG and 
9to13CpG primer sets, and then averaged DNA methylation levels within participants across 
all 9 sites. Once data collection was complete, the full DNA methylation dataset N=152 was 
examined for normality according to bin (1–4 or 5–13) using boxplots, histograms, and the 
Shapiro-Wilk test of normality in IBM SPSS Statistics for Windows, version 22.0 (IBM 
Corp., Armonk, NY). Extreme outliers (more than 3 interquartile ranges from the nearest 
edge of the boxplot) were removed from the dataset to facilitate normality, resulting in a 
final dataset comprised of N=147.
2.8.1. T-tests—Independent samples t-tests were used to test for bivariate associations 
between childhood maltreatment exposure and demographic covariates, as well as MDD and 
demographic covariates, using IBM SPSS Statistics for Windows version 22.0 (IBM Corp., 
Armonk, NY). Chi-square tests were used to test for associations between childhood 
maltreatment exposure and the demographic variables of sex and race. Similarly, Chi-square 
tests were used to test for the association between MDD history and sex and race. All 
statistical tests were two-tailed and results were considered significant with an uncorrected p 
< 0.05.
2.8.2. Regression—Linear regressions were performed separately on each bin to test 
whether childhood maltreatment and MDD have joint and potentially interacting 
relationships on DNA methylation in these regions. In addition to our main variables of 
interest, all regression models included age, sex, race, PBMC viability count and anti-
depressant medication information as covariates. Main effect models were run first, followed 
by interaction models. We addressed the concern of multiple hypothesis testing by 
calculating the false discovery rate (FDR) using the Benjamini Liu method (Benjamini et al., 
2001) for our primary study hypotheses, such that results were accepted as significant when 
pcorrected ≤ 0.012.
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2.8.3. Secondary analyses
2.8.3.1. Gene expression: To examine the potential functional consequences of observed 
DNA methylation differences, we analyzed NR3C1 gene expression values using real-time 
PCR data. Cycle threshold (CT) values for each replicate were averaged to obtain a mean 
CT value for each participant used in our analysis. All data was examined for outliers, and 
any replicates with a standard deviation greater than 0.3 were removed (n=6), and the mean 
CT was re-calculated from remaining data points. Gene expression data were analyzed using 
the comparative CT method (Schmittgen and Livak, 2008), normalizing NR3C1 gene 
expression against the control gene PGK1. Resulting data were analyzed by student's t-test 
to compare expression levels according to the main study variables, as warranted by the 
DNA methylation data, and results were accepted as significant if p < 0.05.
3. Results
Participants with exposure to childhood maltreatment did not differ significantly from those 
without childhood maltreatment exposure in terms of age, sex, or race (Table 1). As 
expected, participants with childhood maltreatment exposure differed from those without 
such exposure for childhood maltreatment score (Table 1); in addition, DNA methylation 
over CpG sites 1–4 was significantly higher in those with vs. without childhood 
maltreatment exposure (Fig. 2). Similarly, MDD cases and controls were significantly 
different for childhood maltreatment score (Table 1); in addition, DNA methylation was 
significantly lower over CpG sites 5–13 in those with vs. without MDD (Fig. 3).
3.1. Main effect and interaction of childhood maltreatment and MDD to predict NR3C1 DNA 
methylation levels
3.1.1. Average DNA methylation CpG sites 1–4—We first examined whether 
childhood maltreatment and MDD predict DNA methylation levels in our study participants, 
with DNA methylation averaged at CpGs 1–4 and 5–13, respectively, as the outcome (Table 
2). In the main effects model for the average DNA methylation of CpG sites 1–4, childhood 
maltreatment significantly predicted DNA methylation levels at CpG sites 1–4, such that 
participants with childhood maltreatment exposure showed increased DNA methylation 
(β=0.038 SE 0.015, pcorrected=0.001); MDD was not associated with DNA methylation in 
this region (pcorrected=0.019) following FDR adjustment, which attenuated the unadjusted 
significant p-value (p=0.026). Age, sex, race, PBMC, and antidepressant medication were 
also not significant in this model (Table 2). In addition, the interaction model showed no 
significant synergistic effect of childhood maltreatment and MDD on NR3C1 DNA 
methylation (Table 2).
3.1.2. Average DNA methylation CpG sites 5–13—For DNA methylation averaged 
across CpG sites 5–13, the main effects models revealed that MDD significantly predicted 
lower DNA methylation (β=−1.038 SE 0.315, pcorrected=0.008). childhood maltreatment 
was not associated with DNA methylation in this region (pcorrected=0.05). In addition, age, 
sex, PBMCs, and antidepressant medication were not significant in this model (Table 2). As 
with sites 1–4, analyses of sites 5–13 showed no significant synergistic effect of childhood 
maltreatment and MDD on NR3C1 DNA methylation (pcorrected=0.05; Table 2).
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3.2. Gene expression of peripheral leukocytes
Results from the regression models suggested independent effects of childhood maltreatment 
and MDD on DNA methylation, thus we chose to separately examine the potential effect of 
childhood maltreatment and MDD on gene expression. T-tests were used to determine 
significant differences in gene expression levels within groups (childhood maltreatment vs 
No childhood maltreatment and MDD vs. No MDD). Results indicated a significant 
(p=0.037) decrease in fold change in the childhood maltreatment group compared to the No 
childhood maltreatment group; no significant expression differences were observed for 
MDD (p=0.27) (Fig. 4).
4. Discussion
The overall goal of this study was to investigate the association of childhood maltreatment 
and MDD with DNA methylation and gene expression of the glucocorticoid receptor in an 
adult population. Our primary analyses sought to test whether childhood maltreatment and 
MDD have a joint and potentially interacting association with NR3C1 DNA methylation. 
Our secondary analyses assessed whether childhood maltreatment and/or MDD-associated 
differences in NR3C1 DNA methylation levels were also associated with differences in gene 
expression. Results from our primary analyses showed that childhood maltreatment exposure 
was associated with an increase in DNA methylation in the upstream region of NR3C1 
tested in our assays, i.e. across the four CpG sites spanning the EGR1 TFBS. Conversely, 
MDD was associated with significant decreases in DNA methylation in the latter half of the 
CpG sites examined (i.e. sites 5–13). No significant childhood maltreatment × MDD 
interactions were observed in either region (1–4 or 5–13), suggesting that there is no effect 
heterogeneity for childhood maltreatment and MDD on DNA methylation within these sites 
of the NR3C1 promoter region. Taken together, results indicate that while childhood 
maltreatment and MDD are both associated with DNA methylation differences the NR3C1 
promoter region, the location and direction of effects differ between the two exposures.
Our finding of increased NR3C1 DNA methylation associated with exposure to childhood 
maltreatment is consistent with previous literature focusing on either childhood 
maltreatment (Martin-Blanco et al., 2014; McGowan et al., 2009; Tyrka et al., 2012) or early 
life experiences (Oberlander et al., 2008; Radtke et al., 2011). Similarly, our MDD results 
are also consistent with a recent study examining NR3C1 DNA methylation levels which 
reported decreased DNA methylation (Na et al., 2014). It should be noted that one other 
study that examined NR3C1 promoter region DNA methylation levels reported a significant 
increase at their CpG site 7 (corresponding to CpG site 5 in this study) in MDD cases 
compared to healthy controls (Nantharat et al., 2015). Additionally, only one of their CpG 
sites overlaps with the region we found to be significantly associated with MDD in our 
study, which is a point of consideration when comparing results. However, neither of these 
studies assessed childhood maltreatment or other adverse life events in their population. 
Despite these findings, our study is distinct from this more recent work as we examined the 
joint and potentially interacting effects of both childhood maltreatment and MDD on NR3C1 
DNA methylation. Interestingly, despite this difference in focus from previous studies, we 
did detect significant differences in DNA methylation associated with childhood 
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maltreatment and MDD, which are consistent with previous studies that examined these 
outcomes separately.
To date, research on NR3C1 DNA methylation has largely focused on the importance of 
early life environment (Oberlander et al., 2008; Radtke et al., 2011; Tyrka et al., 2012). Our 
results, however, identify a significant association between MDD and DNA methylation in 
adults, suggesting that NR3C1 DNA methylation levels are potentially more plastic than 
previously thought; early life environment may not be the only critical window where 
alterations of DNA methylation levels can occur within HPA axis genes. Additionally, we 
did not observe a significant interaction between childhood maltreatment and MDD for CpG 
sites in either of the two bins (1–4 or 5–13). This finding is somewhat surprising given the 
strong body of evidence linking childhood maltreatment exposure with MDD onset (Kendler 
et al., 2004; Nemeroff, 2004) and our significant association of childhood maltreatment and 
MDD with DNA methylation levels. The lack of significant interaction suggests childhood 
maltreatment and MDD influence NR3C1 promoter region DNA methylation levels 
independently of one another.
Our secondary analyses tested whether the observed significant DNA methylation 
differences were reflective of gene expression levels in NR3C1. We found a significant 
decrease in gene expression between individuals with vs. without childhood maltreatment 
exposure. This finding is consistent with previous reports in the literature linking increased 
DNA methylation within the promoter to decreased gene expression (Brenet et al., 2011; 
McGowan et al., 2009), in particular at CpG sites spanning the EGR1 TFBS (Weaver et al., 
2007). Despite finding significantly lower DNA methylation in the downstream region of 
NR3C1 CpG sites associated with MDD, we did not observe significant gene expression 
differences associated with MDD status; however, MDD does not significantly influence 
DNA methylation at the EGR1-associated CpG sites, suggesting that its functional 
consequences (as measured by NR3C1 expression) may be limited compared to the effects 
of childhood maltreatment exposure. This null gene expression finding associated with 
MDD is consistent with a previous study examining DNA methylation and gene expression 
in a group of MDD patients and healthy controls (Nantharat et al., 2015).
It should be noted that several transcripts of NR3C1 exist as a result of alternative splicing. 
The presence of these different transcripts can result in altered glucocorticoid sensitivity 
(Lewis-Tuffin and Cidlowski, 2006; Shahidi et al., 1999). Two of the more prominent 
products of alternative splicing include: glucocorticoid receptor α (GRα) and β (GRβ). 
Multiple studies have reported GRα as the main active isoform (Labonte et al., 2014, 2012; 
Pujols et al., 2002) which works to bind glucocorticoids, while GRβ negatively regulates 
GRα (Hagendorf et al., 2005; Oakley et al., 1996; Pujols et al., 2002). GRα is more 
prevalent in peripheral leukocytes and monocytes compared to GRβ (Hagendorf et al., 2005; 
Pujols et al., 2002), the same tissues used in this study to measure relative gene expression 
and DNA methylation levels of NR3C1, respectively. Our Taqman gene expression assay 
specifically targeted the GRα isoform. Taking into account our finding of decreased mRNA 
expression in those with a history of childhood maltreatment, is it likely that GR-α is down 
regulated among those with this exposure, possibly leading to decreased cortisol sensitivity. 
This notion is supported by a study reporting significantly decreased GRα mRNA 
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expression in participants with PTSD compared to healthy controls. Of particular relevance 
to the current work is the finding that decreased GRα expression was modulated by a dose-
response effect of trauma irrespective of PTSD status, such that those with higher trauma 
loads showed more marked decrease in GRα expression (Gola et al., 2014).
Of particular importance to this study is the issue of tissue specificity in DNA methylation. 
In this study, we report DNA methylation levels derived from a peripheral tissue, blood, and 
do not assess DNA methylation in brain, as our population is composed of living individuals. 
Nevertheless, several studies have examined post-mortem brain tissue samples and report 
similar patterns of DNA methylation as those observed in peripheral tissue (Farre et al., 
2015; McGowan et al., 2009). To assess whether DNA methylation levels within NR3C1 
were consistent between blood and brain tissues, we visualized our regions of interest (see 
methods for coordinates) using the UCSC genome browser (genome.ucsc.edu) and 
MARMAL-AID (marmal-aid.org). NR3C1 DNA methylation levels were similar in both 
tissues, providing further support that the observed changes in blood are potentially a useful 
biomarker of changes occurring in the brain. Additional work in rodents suggests that GR-
responsive genes, including NR3C1, show concordant gene expression changes in brain and 
blood in relation to stress-related phenotypes (Daskalakis et al., 2014), further supporting the 
use of select blood-based measures as biomarkers of stress-related conditions.
4.1. Limitations
It is important to note limitations one must consider when interpreting our results. First, the 
childhood maltreatment variable used in our study is a retrospective self-reported measure 
from each individual of abuses occurring before the age of 18. Even though early life 
experiences have been shown to be long lasting and detected into adulthood, self-reported 
measures may introduce recall bias. Previously, retrospective self-reports of childhood 
maltreatment from adults with documented cases were associated with underreporting of 
physical and sexual abuse (Widom and Morris, 1997; Widom and Shepard, 1996). 
Therefore, our measure of childhood maltreatment may well be an underestimate of previous 
abuse. Second, we report small, yet significant DNA methylation changes and observed 
effect sizes within our data; however, these results are consistent with previous childhood 
maltreatment and depression-related reports of NR3C1 DNA methylation (Labonte et al., 
2014; Oberlander et al., 2008; Tyrka et al., 2012). In addition, the functional effect of 
childhood maltreatment-associated DNA methylation differences on gene expression lends 
support to the relevance of these small effects. Third, although we controlled for PBMC 
viability counts, which did not differ among participants with vs. without childhood 
maltreatment or MDD, we were not able to control for differences in white blood cell 
subsets. Thus it is possible that the childhood maltreatment and/or MDD-associated DNA 
methylation differences might be localized to a particular cell type. Fourth, studies have 
shown that atypical and melancholic subtypes of MDD manifest in different biologic 
pathways (Charmandari et al., 2005; Lamers et al., 2013); however, in our work we were 
unable to subdivide our participants into atypical or melancholic depression based on the 
instrument used within the parent study preventing a more detailed interpretation of our 
findings with regard to MDD subtype. Finally, we were unable to assess whether our 
observed DNA methylation and expression differences in NR3C1 were also associated with 
Bustamante et al. Page 11
J Affect Disord. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
differences in cortisol levels, as such samples were not collected in the original parent study. 
However, related studies suggest that DNA methylation differences are indeed associated 
with differences in cortisol levels (Tyrka et al., 2012), with increased NR3C1 DNA 
methylation associated with reductions in plasma cortisol.
This study also has many strengths. Our study is unique in that we are testing samples from 
a non-clinical, community-based cohort of adult residents in Detroit, providing the 
opportunity to generalize our results to the larger Detroit population. Additionally, our 
analyses included participant antidepressant medication information: controlling for 
medication use in analyses is imperative to accurately interpret data and results, due to 
multiple reports of altered epigenetic signatures following antidepressant medication use 
(Melas et al., 2012; Perisic et al., 2010). Furthermore, our study extends the current 
literature, as we simultaneously examined the association of childhood maltreatment and 
MDD on DNA methylation and gene expression levels within the same study participants. 
Finally, we tested study participants for both gene expression and DNA methylation levels, 
allowing us to infer the potential downstream impact of differences in DNA methylation 
levels.
5. Conclusion
In conclusion, we report significant DNA methylation differences within the promoter 
region of NR3C1 associated with both childhood maltreatment and MDD. We also found a 
significant decrease in NR3C1 gene expression among those exposed to childhood 
maltreatment, however no significant difference in relative gene expression levels was 
observed in MDD. Future work on other HPA axis genes should provide additional insight 
into the joint and potentially interacting effects of childhood maltreatment and MDD on 
stress-relevant DNA methylation.
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Fig. 1. 
Promoter region of NR3C1 examined within this study (CHR5: 142,783,501–142,783,655 
UCSC Genome Browser Build 2009/hg19). CpG sites tested in this study are depicted in 
bold green font (online version) and are also numbered. The EGR1 transcription factor 
binding site is located at CpG sites 3 and 4 and is denoted by underline. The transcription 
start site is indicated by “+1”. Lowercase nucleotides represent intronic regions, while 
uppercase nucleotides represent exon 1F. Figure was adapted from “Prenatal exposure to 
maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) 
and infant cortisol stress responses”, Oberlander et al. Epigenetics April 2008 with 
permission of the publisher (Taylor & Francis Ltd: http://www.tandfonline.com).
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Fig. 2. 
Average DNA methylation among participants with vs. without childhood maltreatment 
(CM) exposure at CpG sites 1–4 and 5–13 within NR3C1, N=147. * denotes statistical 
significance (pcorrected <0.012). The error bars represent standard error of the mean within 
each binned CpG region.
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Fig. 3. 
Average DNA methylation among participants with vs. without MDD history at CpG sites 
1–4 and 5–13 in NR3C1, N=147. * denotes statistical significance (pcorrected < 0.012). The 
error bars represent standard error of the mean within each binned CpG region.
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Fig. 4. 
Fold change of NR3C1 gene expression levels between individuals with vs. without 
childhood maltreatment (CM) exposure and for participants with and without MDD history. 
Paired T-tests show a significant (p = 0.037) decrease in expression among CM cases and 
controls for NR3C1. No significant difference was observed for MDD cases compared to 
controls. Error bars represent standard error of the mean.
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